Comparative Analysis of Vitamin A (Retinol) Regulated Genes in African-American and Caucasian Prostate Cancer Patients

2005 ◽  
Author(s):  
Sue E. Touma ◽  
Lorraine J. Gudas ◽  
David M. Nanus ◽  
Satish K. Tickoo
Keyword(s):  
Prostate Cancer ◽  
African American ◽  
Comparative Analysis ◽  
Vitamin A ◽  
Cancer Patients

scholarly journals Comparative analysis of p16 expression among African American and European American prostate cancer patients

The Prostate ◽  
2019 ◽  
Vol 79 (11) ◽  
pp. 1274-1283 ◽  
Author(s):  
Myra Wong ◽  
Yaeli Bierman ◽  
Curtis Pettaway ◽  
Rick Kittles ◽  
Martha Mims ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
African American ◽  
Comparative Analysis ◽  
Cancer Patients ◽  
European American ◽  
P16 Expression

scholarly journals Dysregulated gene expression predicts tumor aggressiveness in African-American prostate cancer patients

2018 ◽  
Vol 8 (1) ◽  
Author(s):  
Hamdy E. A. Ali ◽  
Pei-Yau Lung ◽  
Andrew B. Sholl ◽  
Shaimaa A. Gad ◽  
Juan J. Bustamante ◽  
...  
Keyword(s):  
Gene Expression ◽  
Prostate Cancer ◽  
African American ◽  
Cancer Patients ◽  
Tumor Aggressiveness

scholarly journals PD40-07 ADDRESSING HEALTH LITERACY IMPROVES SHARED DECISION MAKING IN UNDERSERVED AFRICAN AMERICAN PROSTATE CANCER PATIENTS

2020 ◽  
Vol 203 ◽  
pp. e817-e818
Author(s):  
Kerry Kilbridge ◽  
William Martin-Doyle* ◽  
Christopher Filson ◽  
Quoc-Dien Trinh ◽  
Sierra Williams ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Decision Making ◽  
African American ◽  
Health Literacy ◽  
Cancer Patients ◽  
Shared Decision Making ◽  
Shared Decision

Abstract 4183: Recruiting African-American prostate cancer patients for biobank research

2019 ◽  
Author(s):  
Jennifer Damonte ◽  
Siddhartha Roy ◽  
Carmen Benson ◽  
Kala Jamison ◽  
Hyun Park ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
African American ◽  
Cancer Patients ◽  
Biobank Research

Altered N-myc Downstream-Regulated Gene 1 Protein Expression in African-American Compared with Caucasian Prostate Cancer Patients

2004 ◽  
Vol 10 (1) ◽  
pp. 222-227 ◽  
Author(s):  
Robert P. Caruso ◽  
Benjamin Levinson ◽  
Jonathan Melamed ◽  
Rosemary Wieczorek ◽  
Samir Taneja ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
African American ◽  
Protein Expression ◽  
Cancer Patients

Cancer-related self-efficacy in African American prostate cancer patients compared to whites

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 5067-5067
Author(s):  
J. Q. Purnell ◽  
O. Palesh ◽  
K. Mustian ◽  
L. Peppone ◽  
G. Morrow ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
African American ◽  
Cancer Patients ◽  
Psychological Adjustment ◽  
Psychosocial Functioning ◽  
Self Efficacy ◽  
Healthcare Personnel ◽  
Intervention Method ◽  
Significant Difference ◽  
Therapy Intervention

5067 Background: African American (AA) men are nearly twice as likely as white (W) men to be diagnosed with prostate cancer. Cancer-related self-efficacy (i.e., confidence in one's ability to manage cancer) has been associated with better physical and psychosocial functioning, but little is known about self-efficacy in African American prostate cancer patients. This study compared AA and W ratings of cancer-related self-efficacy for 308 prostate cancer patients (M age = 66.13, SD = 8.48; 9% AA) who participated in a group therapy intervention. Method: Independent groups t-tests were used to determine whether there were significant differences at baseline in mean scores for each group on the Stanford Self-Efficacy Scale (SSE), which asks respondents to rate their confidence in the ability to cope with cancer on a 0–100 scale, with 0 indicating no confidence. SSE subscales measure self-efficacy in the ability to: a) communicate with family, friends, and healtcare providers; b) focus and relax; and c) cope with the possibility of dying. Results: A significant difference was observed on SSE total scores (AA mean = 60.39 vs. W mean = 72.70; t = 3.30; p = 0.003). There were also significant differences on the Focus/Relax (AA mean = 68.90 vs. W mean = 77.64; t = 2.04; p = 0.011) and Cope with Dying (AA mean = 49.72 vs. W mean = 70.12; t = 4.85; p = 0.001) subscales, with a trend towards significance on the Ability to Communicate (AA mean = 62.55 vs. W mean = 70.76; t = 3.36; p = 0.095). Conclusions: Results suggest that, compared to W men, AA men have less confidence in their ability to cope with prostate cancer following diagnosis. AA men report the least confidence in their ability to cope with the possibility of death as a result of cancer, and they also report less confidence in their ability to focus and relax. They may also have greater difficulty discussing their cancer with family, friends, and healthcare personnel. As cancer-related self-efficacy has been linked to symptom-related and psychological adjustment, interventions targeting self-efficacy in AA prostate cancer patients are needed that are tailored to their unique needs. No significant financial relationships to disclose.

Comorbidity burden in prostate cancer patients by ESRD status.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e17510-e17510
Author(s):  
Nagaraju Sarabu ◽  
Weichuan Dong ◽  
Austin Fernstrum ◽  
Al Ray ◽  
Lee Evan Ponsky ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
African American ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Age Groups ◽  
Treatment Modalities ◽  
Fee For Service ◽  
Comorbidity Burden ◽  
Study Population ◽  
Esrd Patients

e17510 Background: The co-occurrence of cancer and end-stage-renal disease (ESRD) may pose significant challenge in the management of both diseases. Further complicating clinical decisions is our limited understanding of the comorbidity burden (CB), which also affects their outcomes to a considerable extent. The purpose of this study is to characterize the CB in prostate cancer patients, with and without ESRD. Methods: Using SEER-Medicare database between years 2000-2016, we retrieved sociodemographic variables, including age (40-54, 55-64, 65-74, and 75+), race (African American vs. all others), marital status (married/partnered vs. all others), residence in a census tract with poverty rate > 20%, and dual Medicare-Medicaid enrollment status; chronic conditions identified in the year of cancer diagnosis; and ESRD status preceding prostate cancer diagnosis. We limited our study population to cancer patients enrolled in Medicare at the time of cancer diagnosis, and were receiving their care through the fee-for-service system. In this descriptive analysis, we compared the prevalence of these conditions between prostate cancer patients by ESRD status. Results: Our study population included 2,046 ESRD and 302,136 non-ESRD men diagnosed with incident prostate cancer during the study period. Compared to non-ESRD patients, a disproportionately higher percentage of ESRD patients were in the 40-54 and 55-64 age groups compared to non-ESRD (11.0 vs 0.95% and 32.2% vs. 8.51%, respectively). Similarly, the percentage of prostate cancer patients who were African American was 44.1% among ESRD patients, compared with 13.6% in their non-ESRD counterparts. With regard to comorbidities, several conditions were significantly higher in ESRD than non-ESRD patients, including: anemia (65.4% vs. 15.3%), congestive heart failure (31.1% vs. 8.9%), ischemic heart disease (38.9% vs. 25.2%), diabetes (40.7% vs. 17.0%), hypertension (68.0% vs. 42.6%), hypothyroidism (4.6% vs. 2.9%), hyperlipidemia (43.1% vs. 35.1%), and stroke (3.7% vs. 2.5%). Conclusions: Compared to their non-ESRD counterparts, ESRD patients present with high CB, severely compromising their physiologic reserve and tolerance for various cancer treatment modalities, and affecting outcomes. Future studies should compare the prevalence of specific combinations of conditions constituting multimorbidity between ESRD and non-ESRD patients, and identify multimorbidity profiles associated with a lower likelihood to receive standard treatment. Such detailed analysis will be foundational to clinical management and outcome studies.

Sign in / Sign up

Export Citation Format

Share Document